itrates for bone protection in chronic kidney disease

Phase 3

• Conditions: Chronic kidney disease; Osteopenia; Musculoskeletal - Osteoporosis; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12614000049673
• Lead Sponsor: The University of Melbourne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-01-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Participants willl have both stage 3 or 4 CKD and either
osteopenia or osteoporosis

Exclusion Criteria

Minimal trauma fractures
Uncorrected vitamin D deficiency (< 50 nmol/L)
PTH > 15 pmols/L
Metabolic bone diseases
Prednisolone > 5 mgs/d
Unexplained elevation of serum alkaline phosphatase

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum alkaline phosphatase.[12 months];Spinal bone mineral density (BMD), measured by dual energy x-ray absorptiometry (DXA).[12 months]

Secondary Outcome Measures

Name	Time	Method
Femoral neck, total hip and distal radius BMD, measured by dual energy x-ray absorptiometry (DXA).[12 months];Serum bone turnover markers (PINP and CTX)[12 months]